



Corrigendum: Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

Wen-Hsuan Tsai^{1†}, Fung-Chang Sung^{2,3,4†}, Lu-Ting Chiu², Ying-Hsiu Shih², Ming-Chieh Tsai¹ and Shu-I Wu^{5,6*}

¹Division of Endocrinology and Metabolism, Department of Internal Medicine, Mackay Memorial Hospital, Taipei, Taiwan, ²Management Office for Health Data (DryLab), Clinical Trial Research Center (CTC), China Medical University Hospital, Taipei, Taiwan, ³Department of Health Services Administration, China Medical University, College of Public Health, Taichung, Taiwan, ⁴Department of Food Nutrition and Health Biotechnology, Asia University, Taichung, Taiwan, ⁵Department of Medicine, Mackay Medical College, New Taipei City, Taiwan, ⁶Department of Psychiatry, Mackay Memorial Hospital, Taipei, Taiwan

Keywords: neuroendocrine, diabetes, glucagon-like peptide-1 receptor agonist, depression, anxiety

A corrigendum on

OPEN ACCESS

Edited and reviewed by:

Dominique Massotte,
Université de Strasbourg, France

*Correspondence:

Shu-I Wu
t140@mmmc.edu.tw

[†]These authors have contributed
equally to this work

Specialty section:

This article was submitted to
Neuropharmacology,
a section of the journal
Frontiers in Pharmacology

Received: 28 February 2022

Accepted: 07 March 2022

Published: 22 March 2022

Citation:

Tsai W-H, Sung F-C, Chiu L-T,
Shih Y-H, Tsai M-C and Wu S-I (2022)
Corrigendum: Decreased Risk of
Anxiety in Diabetic Patients Receiving
Glucagon-Like Peptide-1 Receptor
Agonist: A Nationwide, Population-
Based Cohort Study.
Front. Pharmacol. 13:886343.
doi: 10.3389/fphar.2022.886343

Decreased Risk of Anxiety in Diabetic Patients Receiving Glucagon-Like Peptide-1 Receptor Agonist: A Nationwide, Population-Based Cohort Study

by Tsai, W.-H., Sung, F.-C., Chiu, L.-T., Shih, Y.-H., Tsai, M.-C., and Wu, S.-I. (2022). *Front. Pharmacol.* 13:765446. doi: 10.3389/fphar.2022.765446

In the original article, there was an error in the **Results** section. The following paragraph was written incorrectly:

Both groups were similar in age and gender distributions, with a mean age of 53.33 years (SD 13.04) and 45.06% women (**Table 1**). Most baseline prevalence rates of comorbidities were significantly higher in GLP1-RA users than non-users, except for malignancy and alcoholic liver disease. The uses of other hypoglycemic agents were more prevalent in GLP1-RA users than non-users. The GLP1-RA group also had higher aDCSI scores, higher percentages of white-collar jobs and lived more in more urbanized areas.

This paragraph has been corrected to read as follows:

“Both groups had similar distributions of age, gender, occupation, urbanization and comorbidities, with a mean age of 53.33 years (SD 13.04) and 45.06% women (**Table 1**). Although, the percentage of using metformin was higher in non-GLP1-RA users.”

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Tsai, Sung, Chiu, Shih, Tsai and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.